Evidence behind this recommendation.
Selected studies from our library that inform the recommendations on this page. Evidence grade shown when available.
Randomized controlled trial: Moxibustion and acupuncture for the treatment of Crohn's disease
“This RCT showed that the combination of acupuncture with moxibustion significantly reduced the CDAI (Crohn Disease Activity Index) compared with sham over 8 weeks, with a moderate effect size and low-to-moderate GRADE evidence.”
Acupuncture for gastrointestinal diseases
“This review shows that acupuncture may be a safe and effective option for several digestive disorders, including irritable bowel syndrome, constipation, reflux, and inflammatory bowel disease...”
What Crohn Disease Is
Crohn disease (CD) is a chronic inflammatory bowel disease (IBD) of transmural nature — the inflammation crosses all layers of the intestinal wall, from mucosa to serosa. Unlike ulcerative colitis, CD can affect any segment of the gastrointestinal tract, from mouth to anus, and has a discontinuous distribution (skip lesions), with inflamed segments alternating with healthy stretches.
The most common location is the ileocecal region (terminal ileum + ascending colon), present in 40 to 50% of cases. CD has three behavioral phenotypes: inflammatory (B1), stricturing (B2), and penetrating (B3 — fistulas and abscesses), with a tendency to progress from B1 to B2/B3 over the years. Extraintestinal manifestations — arthropathy, erythema nodosum, uveitis — occur in 25 to 35% of patients.
The clinical picture varies according to location and phenotype. The typical ileocolic form manifests with right iliac fossa pain (mimicking appendicitis), diarrhea without blood (different from UC), fever, and weight loss. Penetrating CD (B3) includes perianal, enteroenteric, or enterovesical fistulas, and intraabdominal abscesses. The nutritional impact — protein-calorie malnutrition in up to 30% of cases — is a constant concern in management.
Conventional Treatments
Treatment of CD is complex and individualized. Unlike UC, aminosalicylates (5-ASA) have limited efficacy in CD. The therapeutic arsenal is escalated according to the severity, location, and phenotype of the disease.
THERAPEUTIC OPTIONS IN CROHN DISEASE
| MEDICATION / INTERVENTION | INDICATION | CONSIDERATIONS |
|---|---|---|
| Oral budesonide | Mild to moderate ileocolic (B1) | Controlled release in the ileum; lower systemic toxicity |
| Systemic prednisone | Moderate to severe; flares | Not indicated for maintenance |
| Azathioprine / Methotrexate | Maintenance; corticodependence | Latency 3–6 months; hepatotoxicity (MTX) |
| Infliximab / Adalimumab | Moderate to severe; B3 fistulas | Anti-TNF; effective in fistula closure |
| Vedolizumab | Gut-selective alternative | Less systemic immunosuppression |
| Ustekinumab | Luminal Crohn; anti-IL-12/23 | Good tolerability; subcutaneous use |
| Surgery | Stricture, abscess, refractoriness | Not curative; postoperative recurrence frequent |
How Acupuncture Works in Crohn Disease
In CD, medical acupuncture acts on the neuro-enteric-immune axis, modulating systemic pro-inflammatory cytokines, regulating intestinal permeability, and promoting microbiome rebalancing via neurovegetative signaling.
Mechanism of Action in Crohn Disease
Stimulation of ST-25 + SP-4
ST-25 (Tianshu) acts via the segmental T10–L2 pathway in the intestine; SP-4 (Gongsun), master point of the Chong Mai, regulates the gut-brain axis via enteric signaling.
Possible modulation of IL-17 and TNF-α
Biopsy studies in small samples describe reduction of IL-17 and TNF-α (on the order of 25%–30%) and reduction of upstream IL-23 after acupuncture; the Th17 pathway is central in CD pathogenesis. Preliminary mechanistic data that do not equate to the pharmacologic effect of anti-TNF biologics.
Restoration of Tight Junctions
Increased expression of occludin and ZO-1 → reduction of intestinal hyperpermeability documented by lactulose/mannitol ratio in RCTs.
HPA Axis Modulation
Studies suggest reduction of serum cortisol and hypothalamic CRH → possible attenuation of the stress response that precipitates relapses. Finding observed in subgroups after weeks of treatment, still with limited evidence.
Microbiome Regulation
Increase of Lactobacillus and Bifidobacterium with reduction of pathogenic Proteobacteria — indirect effect via modulation of motility and mucosal secretion.
Scientific Evidence
Clinical research on acupuncture in CD has grown significantly, with RCTs using the CDAI (Crohn's Disease Activity Index) as the primary outcome and objective inflammatory markers (CRP, IL-6, IL-17) as secondary outcomes.
World J Gastroenterol 2020 — RCT (n=96)
Meta-analysis Complement Ther Med 2019 — 9 RCTs (n=378)
Modern Approach: Integrative Medical Acupuncture
The medical acupuncturist designs an individualized protocol based on the CD phenotype (B1/B2/B3), predominant location, medications in use, and clinical objectives.
CLINICAL PROTOCOL IN CROHN DISEASE
| PARAMETER | SPECIFICATION | OBSERVATION |
|---|---|---|
| Central points | ST-25 + ST-36 + SP-4 | Adapted to predominant location |
| Auxiliary points | LI-11 + ST-37 + CV-12 | According to dominant symptomatology |
| EA frequency | 2–4 Hz (dispersed-dense) | Analgesia + anti-inflammatory |
| Active phase | 2–3 sessions/week for 8–12 weeks | CDAI assessment at the end |
| Maintenance | 1–2 sessions/month in remission | Prevention of relapses |
| Local contraindication | Do not needle the region of an active abscess | Risk of bacterial dissemination |
When to See a Medical Acupuncturist
Ideal Profile for Acupuncture
- CD in remission with residual functional symptoms
- Chronic abdominal pain without correlation with endoscopic activity
- Fatigue and reduced quality of life in remission
- Corticodependence — safe reduction under supervision
- Anxiety and depression associated with CD
Cautionary Situations
- Severe acute flare: prioritize medication treatment
- Active intraabdominal abscess: no local acupuncture
- Acute intestinal obstruction: urgent surgical evaluation
- Severe malnutrition: nutritional support before initiation
Frequently Asked Questions
Frequently Asked Questions
There is no known cure for CD — whether with medication, surgery, or acupuncture. The goal of treatment is to keep the disease in remission, prevent complications, and preserve quality of life. Acupuncture contributes adjuvantly to these objectives, without replacing pharmacotherapy.
There is no evidence that acupuncture closes perianal fistulas — for that, anti-TNF biologics (infliximab) and, frequently, surgical intervention are needed. Acupuncture can help in the control of chronic perineal pain and in the improvement of overall well-being in patients with treated fistulas.
Only under rigorous medical supervision and with CDAI monitoring. Unsupervised reduction of corticosteroids in active CD can precipitate severe flares. Acupuncture can be used as an adjuvant strategy to facilitate gradual corticosteroid withdrawal, but always with gastroenterologic follow-up.
RCTs demonstrate clinical benefit after 8 to 12 weeks of treatment. In the active phase, 2 to 3 weekly sessions are recommended. In remission, monthly maintenance sessions are sufficient for most patients.
Yes, with no known interactions. The combination is pathophysiologically rational, as acupuncture acts through neuroimmunologic pathways distinct from biologics (vagal/cholinergic vs. anti-IL-12/23 or anti-integrin), potentially generating a complementary effect.
Related Articles
Immunologic modulation via vagal reflex in UC
Acupuncture for Functional DyspepsiaNormalization of gastric emptying
Acupuncture for Functional Abdominal PainVisceral hyperalgesia and gut-brain axis
Acupuncture for Chronic ConstipationCONSTIPATE trial Lancet 2020: level 1 evidence